Mahesh Basyal
Overview
Explore the profile of Mahesh Basyal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu G, Zhang W, Basyal M, Nishida Y, Mizumo H, Ly C, et al.
Leuk Lymphoma
. 2024 Jun;
65(11):1659-1674.
PMID: 38871487
Despite the development of several Fms-like tyrosine kinase 3 () inhibitors that have improved outcomes in patients with -mutant acute myeloid leukemia (AML), drug resistance is frequently observed, which may...
2.
Short N, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, et al.
J Hematol Oncol
. 2023 Jul;
16(1):73.
PMID: 37422688
Background: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat...
3.
Senapati J, Muftuoglu M, Ishizawa J, Abbas H, Loghavi S, Borthakur G, et al.
Blood Cancer J
. 2023 Jun;
13(1):101.
PMID: 37386016
In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses...
4.
Carter B, Mak P, Muftuoglu M, Tao W, Ke B, Pei J, et al.
Blood
. 2023 Jun;
142(12):1056-1070.
PMID: 37339579
TP 53-mutant acute myeloid leukemia (AML) remains the ultimate therapeutic challenge. Epichaperomes, formed in malignant cells, consist of heat shock protein 90 (HSP90) and associated proteins that support the maturation,...
5.
Jia Y, Zhang W, Basyal M, Chang K, Ostermann L, Burks J, et al.
Leukemia
. 2023 Apr;
37(6):1379-1383.
PMID: 37085610
No abstract available.
6.
Yu G, Zhang W, Zhang H, Ly C, Basyal M, Rice W, et al.
Res Sq
. 2023 Mar;
PMID: 36865133
Background: Despite the development of several FLT3 inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemias (AML), drug resistance is frequently observed, which may be associated with...
7.
Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, et al.
Haematologica
. 2022 Oct;
108(6):1500-1514.
PMID: 36226489
Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed. We identified autophagy as one of the resistance mechanisms, induced by...
8.
Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan M, et al.
JCI Insight
. 2022 Mar;
7(7).
PMID: 35230977
SARS-CoV-2 vaccines pose as the most effective approach for mitigating the COVID-19 pandemic. High-degree efficacy of SARS-CoV-2 vaccines in clinical trials indicates that vaccination invariably induces an adaptive immune response....